Management of hyperphosphataemia in chronic kidney disease-challenges and solutions

Clinical Kidney Journal

Volumn 6, Issue 2, 2013, Pages 128-136

  Ketteler, Markus ^a   Wüthrich, Rudolf P ^b   Floege, Jürgen ^c  

^a KfH Kidney Center Coburg   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

chronic kidney disease; hyperphosphataemia; phosphate binder

Indexed keywords

ALUMINUM; CALCIMIMETIC AGENT; CALCIUM ACETATE; CALCIUM CARBONATE; CHITOSAN; COLESTILAN; FERRIC CITRATE; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; NICOTINAMIDE; NICOTINIC ACID; PA 21; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; UNCLASSIFIED DRUG;

CHRONIC KIDNEY DISEASE; DIET RESTRICTION; DIETARY INTAKE; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPHOSPHATEMIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW;

EID: 84875721406     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfs173     Document Type: Review

References (98)

1. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008; 8: 117
2. Couser WG, Remuzzi G, Mendis S et al. The contribution of chronic kidney disease to the global burden of major non-communicable diseases. Kidney Int 2011; 80: 1258-1270
3. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 76: S1-S130
4. Kasiske BL, Zeier MG, Chapman JR et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77: 299-311
5. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-897
6. Gonzalez-Parra E, Tunon J, Egido J et al. Phosphate: a steal-thier killer than previously thought? Cardiovas Pathol 2012; 21: 372-381
7. Floege J, Kim J, Ireland E et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955
8. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
9. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium× phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
10. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. JASN 2004; 15: 2208-2218
11. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. JASN 2005; 16: 1788-1793
12. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010; 362: 1312-1324
13. Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011; 7: 578-589
14. Miyamoto K, Haito-Sugino S, Kuwahara S et al. Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. J Pharm Sci 2011; 100: 3719-3730
15. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
16. Naveh-Many T, Bell O, Silver J et al. Cis and trans acting factors in the regulation of parathyroid hormone (PTH) mRNA stability by calcium and phosphate. FEBS Lett 2002; 529: 60-64
17. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. JASN 2009; 20: 1453-1464
18. Sigrist MK, Taal MW, Bungay P et al. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. CJASN 2007; 2: 1241-1248
19. Russo D, Corrao S, Battaglia Y et al. Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int 2011; 80: 112-118
20. Block GA. Screening dialysis patients for vascular calcification. Semin Dial 2010; 23: 271-276
21. Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. JASN 2012; 23: 1407-1415
22. Russo D, Miranda I, Ruocco C et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-1261
23. KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S11-S145
24. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378
25. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
26. Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. JASN 2011; 22: 1913-1922
27. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747
28. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? CJASN 2010; 5: 286-291
29. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012; 92: 131-155
30. Isakova T, Gutiérrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 2009; 76: 705-716
31. Evenepoel P, Meijers B, Viaene L et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogen-esis of secondary hyperparathyroidism. CJASN 2010; 5: 1268-1276
32. Bacchetta J, Salusky IB. Evaluation of hypophosphatemia: lessons from patients with genetic disorders. Am J Kidney Dis 2012; 59: 152-159
33. Zoppellaro G, Faggin E, Puato M et al. Fibroblast growth factor 23 and the bone-vascular axis: lessons learned from animal studies. Am J Kidney Dis 2012; 59: 135-144
34. Kirkpantur A, Balci M, Gurbuz OA et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant 2011; 26: 1346-1354
35. Mirza MA, Larsson A, Melhus H et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 546-551
36. Seiler S, Cremers B, Rebling NM et al. The phosphatonin fibro-blast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011; 32: 2688-2696
37. Shalhoub V, Shatzen EM, Ward SC et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyr-oidism yet increases mortality. J Clin Invest 2012; 122: 2543-2553
38. Yilmaz MI, Sonmez A, Saglam M et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012; 59: 177-185
39. Port FK, Pisoni RL, Bommer J et al. Improving outcomes for dialysis patients in the international dialysis outcomes and practice patterns study. CJASN 2006; 1: 246-255
40. Noori N, Kalantar-Zadeh K, Kovesdy CP et al. Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. CJASN 2010; 5: 683-692
41. Heng A-E, Cano NJM. Nutritional problems in adult patients with stage 5 chronic kidney disease on dialysis (both hae-modialysis and peritoneal dialysis). NDT Plus 2010; 3: 109-117
42. Shinaberger CS, Greenland S, Kopple JD et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 2008; 88: 1511-1518
43. Lynch KE, Lynch R, Curhan GC et al. Prescribed dietary phosphate restriction and survival among hemodialysis patients. CJASN 2011; 6: 620-629
44. Ritz E, Hahn K, Ketteler M et al. Phosphate additives in food-a health risk. Dtsch Arztebl Int 2012; 109: 49-55
45. Uribarri J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial 2007; 20: 295-301
46. Gutiérrez OM, Anderson C, Isakova T et al. Low socioeco-nomic status associates with higher serum phosphate irrespective of race. JASN 2010; 21: 1953-1960
47. Uribarri J. Phosphorus additives in food and their effect in dialysis patients. CJASN 2009; 4: 1290-1292
48. Cupisti A, Ferretti V, D'Alessandro C et al. Nutritional knowledge in hemodialysis patients and nurses: focus on phosphorus. J Ren Nutr 2012; 22: 541-546
49. Sullivan C, Sayre SS, Leon JB et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 2009; 301: 629-635
50. Isakova T, Gutiérrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. JASN 2009; 20: 388-396
51. Cannata-Andia JB. The use of phosphate binding agents is associated with lower mortality: results from the COSMOS study. Paris, France: 49th ERA-EDTA Congress, May 24-27, 2012
52. Lopes AA, Tong L, Thumma J et al. Phosphate binder use and mortality among hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012; 60: 90-101
53. Barreto FC, de Oliveira RA, Oliveira RB et al. Pharmacotherapy of chronic kidney disease and mineral bone disorder. Expert Opin Pharmacother 2011; 12: 2627-2640
54. Graf H, Stummvoll HK, Meisinger V. Dialysate aluminium concentration and aluminium transfer during haemodialysis. Lancet 1982; 319: 46-47
55. Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hy-perphosphatemia in hemodialysis patients: the calcium acetate renagel evaluation (CARE study). Kidney Int 2004; 65: 1914-1926
56. Brewster UC, Ciampi MA, Abu-Alfa AK et al. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders. Nephrology 2006; 11: 142-146
57. Jean G, Lataillade D, Genet L et al. Calcium carbonate, but not sevelamer, is associated with better outcomes in hemo-dialysis patients: results from the French ARNOS study. He-modial Int 2011; 15: 485-492
58. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
59. Moe SM, Chertow GM. The case against calcium-based phosphate binders. CJASN 2006; 1: 697-703
60. Wrong O, Harland C. Sevelamer. Nephrol Dial Transplant 2008; 23: 2108; author reply 2101-2102
61. De Santo NG, Frangiosa A, Anastasio P et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006; 19: S108-S114
62. Delmez J, Block G, Robertson J et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007; 68: 386-391
63. Pai AB, Shepler BM. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 2009; 29: 554-561
64. Navaneethan SD, Palmer SC, Vecchio M et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011; CD006023
65. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemo-dialysis patients. Kidney Int 2007; 72: 1130-1137
66. Molony D, Bellasi A, Bellizzi V et al. Sevelamer Attenuates CV Mortality in Incident Hemodialysis Patients: Open Label, Randomized Clinical Trial of Efficacy and Safety (Independent Study). Paris, France: 49th ERA-EDTA Congress; 24-27 May 2012, 2012
67. Di Iorio B, Bellasi A, Russo D et al. Mortality in kidney disease patients treated with phosphate binders: a randomized study. CJASN 2012; 7: 487-493
68. Iimori S, Mori Y, Akita W et al. Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol 2012; 16: 930-937
69. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815-1824
70. Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004; 13:134-141
71. Braun J, Asmus HG, Holzer H et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004; 62: 104-115
72. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
73. Qunibi W, Moustafa M, Muenz LR et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965
74. Takei T, Otsubo S, Uchida K et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract 2008; 108: c278-c283
75. Zhang Q, Li M, Lu Yet al. Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract 2010; 115: c259-c267
76. Kakuta T, Tanaka R, Hyodo T et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011; 57: 422-431
77. Brandenburg VM, Schlieper G, Heussen N et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010; 25: 2672-2679
78. Finn WF. SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clinical Nephrol 2006; 65: 191-202
79. Sprague SM, Ross EA, Nath SD et al. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clinical Nephrol 2009; 72: 252-258
80. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant 2011; 26: 2567-2571
81. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; 85: S73-S78
82. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, toler-ability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100: c8-c19
83. Joy MS, Kshirsagar A, Candiani C, Brooks T, Hudson JQ. Lanthanum carbonate. Ann Pharmacother 2006; 40: 234-240
84. Lacour B, Lucas A, Auchère D et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005; 67: 1062-1069
85. Hutchison AJ, Barnett ME, Krause R et al. Lanthanum Carbonate Study Group. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis. Clinical Nephrol 2009; 71: 286-295
86. Arenas MD, Malek T, Álvarez-Ude F et al. Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control. Nefrologia 2010; 30: 522-530
87. Arenas MD, Malek T, Gil MT et al. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol 2010; 23: 525-534
88. Karamanidou C, Clatworthy J, Weinman J et al. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008; 9: 2
89. Chiu YW, Teitelbaum I, Misra M et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. CJASN 2009; 4: 1089-1096
90. Daugirdas JT, Chertow GM, Larive B et al. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. JASN 2012; 23: 727-738
91. Cheng SC, Young DO, Huang Y et al. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. CJASN 2008; 3: 1131-1138
92. Delanaye P, Weekers L, Krzesinski JM. Diarrhea induced by high doses of nicotinamide in dialysis patients. Kidney Int 2006; 69: 1914
93. de Francisco AL, Leidig M, Covic AC et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemo-dialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010; 25: 3707-3717
94. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clinical Nephrol 2010; 74: 4-11
95. Wüthrich RP, Chonchol M, Covic A et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialy-sis patients. Clin J Am Soc Nephrol 2012; [Epub ahead of print]
96. Umanath K, Sika M, Niecestro R et al. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int 2012; doi: 10.1111/j.1542-4758.2012.00711.x.
97. Savica V, Calò LA, Monardo P et al. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. JASN 2009; 20: 639-644
98. Locatelli F, Dimkovic N, Pontoriero G et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant 2010; 25: 574-581